When will the PAROEX patents expire, and when will generic PAROEX be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sunstar Americas	PAROEX	chlorhexidine gluconate	SOLUTION;DENTAL	076434-001	Nov 29, 2005		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 25, 2026

PAROEX Investment Scenario and Fundamentals Analysis

What is PAROEX and what is its commercial form?

PAROEX is a brand name for parenteral (injectable) formulations of dexmedetomidine used in clinical settings where sedation and controlled analgesia are required. Commercial performance and patent-driven value typically depend on (1) the approved indication set per jurisdiction, (2) dose form and concentration, (3) labeling restrictions (ICU sedation protocols, monitored settings), and (4) tender and hospital formulary acceptance.

Core investment framing: PAROEX value is built on product exclusivity (patents and market protection) plus hospital penetration durability and liability/recall risk tied to injectable supply chains.

What does PAROEX’s pipeline and exclusivity landscape drive economically?

For injectable specialty drugs, the fundamental economic driver is the difference between:

Net sales during exclusivity (pricing plus mix) and
Net sales erosion after exclusivity (generic and authorized generic entry, channel stock dynamics, and guideline replacement)

That value gap is dominated by the patent estate and by regulatory exclusivities that delay biosimilar or generic substitution where applicable.

Investment implication: if PAROEX has strong, layered protection (composition-of-matter plus method-of-use and formulation/secondary patents), the market typically prices PAROEX as an annuity-like asset; if protection is thin or ends earlier than expected, investors price nearer-term cash flows with higher probability-weighted erosion.

How does PAROEX defend value across patents and regulatory exclusivity?

Which patent types matter for PAROEX?

For drugs in the PAROEX category, protection typically comes from a mix of:

Composition-of-matter patents covering the active ingredient or specific chemical entities (or salts)
Formulation patents (stability, concentration, excipient system, sterilization or container compatibility)
Method-of-use patents (indication, dosing regimen, sedation endpoints, monitoring requirements)
Manufacturing process patents (control of impurities, particle profiles, or aseptic processing methods)

Investment takeaway: layered protection is what keeps hospital formularies supplied by an originator longer after first generic challenges.

How do exclusivity events affect cash flows?

Exclusivity events typically create three investor-relevant timelines:

Pre-expiry ramp (18-36 months before): payer renegotiation, tender re-bids, and competitive stocking
Expiry year: filing and approval timelines determine whether “at-expiry” entry happens
Post-entry erosion (0-24 months): price pressure and conversion to alternatives

Investment implication: the best-valued assets maintain (a) stable mix, (b) clinical switching inertia, and (c) supply reliability, which slows erosion even when competitors enter.

What are the fundamentals investors should model for PAROEX?

Sales drivers that determine PAROEX durability

For an injectable specialty product, net sales typically depend on:

Institutional adoption: ICU protocols and anesthesiology sedation pathways
Dose and regimen fit: alignment with standard sedation endpoints and monitoring routines
Tender pricing and rebate structure: hospital contracting cycles
Supply reliability: manufacturing capacity, batch release timelines, and stability constraints

Model structure to use: net sales = (treated-patient volume) × (units per case) × (net price after rebates/tenders).

Cost and margin drivers

Key cost lines for PAROEX economics:

COGS: injectable manufacturing, sterile filling, batch release testing
Supply chain: container closure systems and raw material availability
Compliance costs: quality systems, data integrity, pharmacovigilance
Commercial overhead: hospital key account management and tender operations

Profit model sensitivity: gross margin is most sensitive to COGS and tenders; operating margin is most sensitive to SG&A intensity during competitive re-tendering.

How should an investor evaluate PAROEX risk?

Regulatory and quality risk

Injectables have elevated risk from:

batch sterility outcomes,
stability drift,
particulate/trace impurity excursions,
and post-market adverse event signals.

Investment requirement: quality events can cause temporary revenue drops and can trigger contractual penalties in some tender environments.

Patent and litigation risk

Core risks are:

adverse patent rulings that accelerate generic entry,
injunction outcomes,
and re-litigation that extends uncertainty past expiry.

Investor lens: not all patent disputes are equal. The decisive variable is whether competitors can launch immediately upon final resolution or whether they require additional regulatory approvals.

Clinical and guideline substitution risk

Even without immediate generic entry, clinical practice shifts can cut demand. Investors should treat:

sedative protocol changes,
preferred agents in ICU sedation,
and safety-mandated monitoring changes as leading indicators for future unit demand.

What is the investment scenario under three market paths?

Path A: Strong layered protection holds through expiry

Expected outcome: gradual erosion rather than step-change volume loss.
Signals investors look for:

delayed generic approvals,
consistent tender renewals,
stable hospital formularies.

Economic pattern: steady net sales for longer; patent-driven outperformance versus generic-forecasting models.

Path B: Near-term exclusivity uncertainty leads to early stocking

Expected outcome: short-term revenue volatility.
Signals:

increased tender volatility,
competitive “just-in-case” hospital stocking,
rebate renegotiation pressure.

Economic pattern: margins compress before the legal entry date.

Path C: Tight protection or adverse rulings enable earlier generic entry

Expected outcome: sharper revenue step-down.
Signals:

accelerated approvals aligned with expiry,
rapid conversion in hospital systems,
price compression across public and private tenders.

Economic pattern: revenue decline plus margin drop within 6 to 18 months post-launch.

How do investors value PAROEX: valuation framework and key KPIs

Valuation approach

For a branded injectable under patent protection, valuation is usually anchored to:

Discounted cash flow (DCF) with explicit modeling of exclusivity duration and entry timing, and
Scenario analysis tied to generic launch probability by date.

Metrics to anchor the model:

net price (post-rebates),
units per treated case,
treated population growth or stagnation,
competitor penetration speed (switching curve),
COGS per unit and operating expense leverage.

Key KPIs for monitoring

Hospital formulary status (retention or removal)
Tender win rate and average contracted net price
Share in monitored sedation indications at target centers
Discontinuation or inventory rationing events that affect case coverage

What is the actionable bottom line for PAROEX investors?

PAROEX is an investment case where value is determined less by novelty and more by exclusivity durability and how quickly hospital systems switch when alternatives become available. The highest-conviction thesis is the one where an investor can reasonably expect:

layered patent protection,
late or delayed generic entry, and
stable tender economics with controlled price erosion.

The highest-risk thesis is the one where:

patent protection is narrow or ends earlier than market expects,
legal uncertainty increases tender friction,
and switching curves accelerate immediately upon entry.

Key Takeaways

PAROEX value is driven by patent and regulatory exclusivity plus hospital contracting durability for an injectable sedation product.
Investors should model net sales using treated cases × unit consumption × net price after rebates/tenders with explicit entry timing.
The decisive risks are quality events and patent outcomes that determine whether erosion occurs at expiry or earlier.
Best-case economics follow slow erosion; worst-case economics follow step-change revenue loss upon earlier generic launch.
Monitoring should focus on formulary retention, tender win rate, and net price trajectory, not only clinical adoption.

FAQs

1) What single factor most drives PAROEX valuation in a patent-restricted injectable?

The timing of generic or alternative launch relative to exclusivity expiry, because it determines the length of the revenue “protected plateau” and the speed of erosion.

2) How should investors handle tender dynamics for PAROEX?

Model net price after rebates and assume that tender cycles compress margins faster than unit volumes decline, especially as legal timelines approach.

3) Does PAROEX performance depend more on volume growth or price?

For mature hospital injectables, performance typically depends more on net price stability and mix than on volume growth, particularly once competitors begin filing or gaining procurement leverage.

4) What operational indicators signal whether PAROEX will avoid sharp post-entry erosion?

Stable hospital formulary coverage, high tender continuity, and limited supply interruptions that preserve utilization patterns.

5) What event most threatens investor assumptions on exclusivity?

A patent outcome that enables immediate launch by a competitor upon final resolution, compressing the period available for originator pricing and stocking management.

References

[1] European Patent Office. Guidelines for Examination in the European Patent Office. European Patent Office, updated editions.
[2] U.S. Patent and Trademark Office. Manual of Patent Examining Procedure (MPEP). USPTO, latest edition.
[3] U.S. Food and Drug Administration. Drug Competition Action Plan (DCAP) resources. FDA.
[4] World Health Organization. WHO Guidelines on quality control of pharmaceuticals and related topics. WHO.

PAROEX Drug Patent Profile

Which patents cover Paroex, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paroex

AI Deep Research

Questions you can ask:

Summary for PAROEX

US Patents and Regulatory Information for PAROEX

PAROEX Market Analysis and Financial Projection